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LEVAMISOLE is an agent known to be
capable of restoring impaired immune
response in a wide variety of clinical dis-
orders (Symoens & Rosenthal, 1977).
Some discrepancies have been seen in
results of human cancer immunotherapy
with levamisole (Amery & Verhaegen,
1978; Martin, 1979). Until now, neither
chemo- nor immunotherapy has proved
an efficient adjuvant to surgery in human
colorectal cancer. We have tested the
activity of levamisole on the local recur-
rence of tumours and the spread of meta-
stases after surgery, in a model of trans-
planted intestinal cancer.
Experimental procedure
Two serially graftable tumour lines,
DHB and DHD were obtained indepen-
dently from adenocarcinomas induced by
1,2 dimethylhydrazine in syngeneic BDIX
rats (Martin et al., 1973). Levamisole was
freshly prepared in phosphate-buffered
saline (PBS).
Experiment 1 was designed to test the
effect of levamisole on metastases. Small
pieces of DHB tumour (- 50 mg) were
s.c. grafted in 24 rats. Tumour growth
developed in 16 rats. Two months after
grafting, the tumour was excised incom-
pletely so that a recurrence might occur.
Rats were randomized in two groups of
8 animals. 8 days after surgery, one group
received repeated weekly i.p. injection of
levamisole (2.5 mg/kg) in 1 ml PBS, the
other group, weekly injections of PBS.
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Recurrent tumours were excised from
animals of both groups, 1, 2 or 3 times,
according to the size of the tumour, to
control the local tumour burden. The
number of excisions was identical in
both groups (2 rats once, 3 rats twice,
and 3 rats thrice). The number of leva-
misole and placebo injections was the same
for all rats (10 injections). All rats were
killed 4 months after receiving thegraft.
Experiment 2 tested the effect of leva-
misole on local and metastatic recurrence
after curative excision. S.c. grafts of line
DHD were transplanted into 40 rats, but
only 31 rats were available for randomiza-
tion and analysis. When the surface of the
tumour reached , 8 cm2 the tumour was
removed surgically and all visible neo-
plastic tissue was excised. Eight days after
surgery, 16 animals received i.p. 2-5 mg/kg
levamisole diluted in 1 ml PBS on two
consecutive days once a week and 15
animals PBS alone, until sacrifice or
until the animals became moribund.
At the end of Expts 1 and 2, animals
had their lungs injected post-mortem with
Evans blue in order to count the number
ofmetastases. Tumour, orgraft bed, lungs,
axillary, pectoral and mediastinal lymph
nodes, liver, spleen, gastrointestinal tract
and kidneys were systematically processed
for histology.
In Expt 1, at sacrifice 6/8 rats in the
levamisole group had lung metastases
versus 7/8 controls. The total number of
lung metastases in the levamisole groupLEVAMISOLE AS AN ADJUVANT TO SURGERY 465
TABLE.-Effectoflevamisole treatmentinratswithDHBorDHDintestinaladenocarcinoma
transplants
Expt 1 (DHB) Expt 2 (DHD)
Levamisole Control Levamisole Control
Mean tumour weight at excision (g) 3-59 (0 68)* 4 59 (0-76) 8-53 (0.48) 8-08 (0.64)
Time betweengraft andexcision (days) 61 61 67 (3 7) 84 (12-7)
Meantumourweight at sacrifice (g) 4-28 (0.78) 4-10 (0-71) 9-58 (1-17) 9-88 (4.54)
Survivalafter excision (days) 59 59 75 (7.1) 77 (12-2)
Total survivalafter grafting (days) 120 120 143 (8.4) 162 (17-9)
Local recurrence 8/8 8/8 7/16 5/15
Pulmonary metastases 6/8 7/8 14/16 12/15
Mediastinal metastases 4/8 3/8 9/16 7/15
Renal metastases 0/8 2/8 6/16 7/15
Curedanimals 0/8 0/8 2/16 3/15
* S.e. in parentheses.
was 44 versus 69 in control rats (not
significant). Mediastinal spread was seen
in both groups. Kidney metastases occur-
red only in 2 control animals. No statis-
tically significant difference was found
between control and treated animals.
In Expt 2 lung metastases were so
numerous in both groups (often more than
100 in one rat) and the size of the meta-
static nodulesvaried so much (from04 mm
to 1 cm in diameter) that it was impossible
to count and evaluate them quanti-
tatively. There wasnosignificantdifference
between levamisole-treated rats and con-
trols, either in survival after surgery or
in local recurrence and metastases. The
number of cured animals was rather low,
2 out of 16 in levamisole group, 3 out of
15 in control group. Results ofExpts 1 and
2 are summarized in the Table.
Since the report of Renoux & Renoux
(1972) who obtained complete prevention
ofrecurrence and areductioninpulmonary
metastases in mice grafted with Lewis
tumours, contradictory results have been
obtained showing no effect (Hard, 1977;
Hopper et al., 1975; Potter et al., 1974),
some decrease in tumour growth and dis-
semination (Aleksic et al., 1977) or an
enhancing effect (Fidler & Spitler, 1975;
Sampson et al., 1977). Amery et al. (1977)
define the best conditions for drug effi-
ciency: (1) The best results are obtained
with 2-5 mg/kg. (2) Levamisole is more
effective on slow-growing tumours. (3) It
affects preferentially metastasis forma-
31*
tion. (4) It should be used as an adjuvant
treatment.
In this work levamisole has been tested
as an adjuvant to surgery, at the dosage
of 2-5 mg/kg. Colonic carcinoma trans-
plants are growing slowly; the mean tu-
mour take is 20 days for DHD and 25 days
for DHB (Martin et al., 1976). In Expt 1,
only the spread ofmetastases was studied,
since local recurrence had purposely been
allowed to occur by incomplete tumour
excision. In Expt 2, total tumour resection
was performed, but the probability of
recurrence or metastasis was high, since
tumour weight was important at the time
of surgery. The situation was very close
to that of patients with human Dukes'
B or C colonic carcinoma. Even when the
conditions of levamisole administration
were very close to the "ideal" situation
defined by Amery et al. (1977) our results
were entirely negative. The extrapolation
ofresults obtained in experimental work to
the clinical situation is difficult; however
the data reported above do not support
the treatment of human colorectal cancer
with levamisole.
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